EryonStudio, healthcare motion design studio
Our films, the method, the communication kit and the process, from idea to final version.
EryonStudio
Uses
Mechanism of action animation
Mechanism of action animation, every step with its evidence
A mechanism of action animation, or MoA video, shows what a medicine does, from its target to the organ, for physicians, pharmacists and your own teams. EryonStudio, Eryon's video studio in Lille, France, writes it for medical affairs, scientific communication and product managers: every mechanism carries its source, its exact passage and the origin of its data. The first version arrives within a few days; the films we have made for pharmaceutical companies are shown in meetings, with their written consent.
The video at a glance
- Audience Physicians and pharmacistsAnd your teams: medical representatives, medical information, training
- Suggested length One to three minutesShorter excerpts for sales calls and congresses
- First version Up to 60 secondsWithin a few days, in motion design, in the language you choose
- Evidence Justification fileEvery line, its reference, its page, its exact passage
- Quote After the first versionYou judge it on screen before ordering the rest
If promotional and shown in France, the video needs the ANSM visa before any release
From target to organ, what the animation must show
Six points separate an animation that merely illustrates from a film your MLR review can approve.
-
The target and the binding, at molecular scale
Receptor, enzyme, channel or antigen: the video shows where the molecule binds and what that binding changes. This is the part that text describes worst and images make obvious, provided they stay accurate.
-
The cascade, from cell to organ
Binding sets off a sequence of events: a signal activated or blocked, a cell that changes its behaviour, an effect on the tissue. Every change of scale is announced on screen, so viewers always know whether they are looking at a molecule, a cell or an organ.
-
The origin of the data for each mechanism
Observed in patients, in vitro or in animals, or only proposed: the voice-over and the screen say so for every mechanism. Your MLR reviewers see at once what has been observed in humans and what has only been seen in animals or in vitro, or remains a hypothesis.
-
A drug mechanism of action animation true to the SmPC
In an advertisement, every element must comply with the summary of product characteristics (SmPC), whose section 5.1 describes the mechanism of action when it is known. The script starts from that text and the cited publications; any discrepancy is flagged before the first frame.
-
Pharma motion design, in your brand guidelines
Molecules, cells and organs in medical animation, diagrams in motion design, your brand's colours and typefaces. Diagrams remain illustrations, simplified and not to scale, and the screen says so.
-
A pharma MoA video, promotional or scientific
In France, the version for sales calls is an advertisement, subject to the visa of the ANSM, the French regulator. The version that answers a doctor's specific question falls under your medical information. Same science, same sources: we write each version for its use, with its statements.
An inhibitor takes the place of ATP
This studio illustration shows a protein kinase in cross-section: ATP, its natural substrate, leaves its pocket, then a competitive inhibitor, in blue, settles in its place. This is the scale of a mechanism of action animation: the target, the binding, then the effect on the cell, each step with the type of data that supports it.
From launch to congress, the same science
One mechanism serves several audiences; each has its own statements, its own approval process and, for promotion in France, its own visa.
A medicine launch: the video serves as a detailing aid and plays on the congress stand, with the ANSM visa.
Training medical representatives and medical teams before a launch, in an internal version that is never shown during sales calls.
Your medical information team's answer to a doctor's specific question, in a non-promotional version.
A biotech before marketing authorisation: explaining a mechanism or a platform to investors, partners or a scientific committee.
An SmPC update, a new indication or new data: the film is revised from its justification file.
Every mechanism, the origin of its data
For a mechanism of action, every step is checked against its source, with the origin of its data, then compared with section 5.1 of the SmPC, before the first frame.
- 01
Scoping, in 30 minutes
Objective, audience, where the video will be shown, available references and regulatory points to watch.
- 02
The referenced script
Every line is tied to a reference, with its page and the exact passage that supports it.
- 03
The visuals
Motion design and medical animation, with AI assisting part of the production. Diagrams remain illustrations.
- 04
Checks and delivery
An automated check finds every passage, word for word, on the page cited; two independent AI-assisted audits then re-check a sample in the documents; your review committee, or your MLR review in a pharmaceutical company, approves the final version.
What you receive
If the video is an advertisement shown in France, its adapted versions are prepared with it: the ANSM recommends submitting them with the initial visa application.
The film and its broadcast files
Landscape for your website, YouTube and the training room; portrait, square or 4:5 for social media.
Subtitles and transcript
SRT file and full text: accessibility, viewing without sound and search visibility for the page that hosts the film.
The script and the justification file
Every line, its reference, its page and the exact passage, ready for your internal review.
The bibliographic references
The full list, in order of appearance, with links to the public sources.
The versions you need
Short excerpts, stills, a poster or slides, depending on your channels. Quoted with the final version.
Languages
The languages you choose: every translated line keeps its source and exact passage, and the rules of the country where the video is shown are checked at scoping.
The ANSM visa, the SmPC and medical information
In France, a video that promotes a medicine to healthcare professionals is an advertisement: it needs the ANSM visa before release (Article L.5122-9 of the French Public Health Code), respects the marketing authorisation (Article L.5122-2) and stays consistent with the SmPC (Directive 2001/83/EC, Article 87). According to the ANSM, a pharmacological property without a clinical consequence validated by the marketing authorisation cannot be its main message. What makes it advertising is the aim of promoting, not the venue, congresses included; correspondence answering a specific question about a medicine, with its non-promotional documents, is not advertising (Article L.5122-1). We write the script and its justification; classifying each use and the visa are the responsibility of your responsible pharmacist, the pharmacien responsable (Article R.5124-36).
Frequently asked questions
What is a medicine's mechanism of action?
It is the way a medicine produces its effect: the target it acts on, what its binding changes there, then the consequences for the cell and the organ. In the SmPC, it appears in section 5.1, Pharmacodynamic properties, when it is known. Pharmacokinetics, that is absorption, distribution, biotransformation and elimination, belongs to section 5.2. A mechanism of action animation shows pharmacodynamics first; pharmacokinetics can have a sequence of its own.
Does a mechanism of action video need an ANSM visa?
Yes, as soon as it promotes a medicine to healthcare professionals in France: it is an advertisement, subject to the visa before any release (Article L.5122-9 of the French Public Health Code). Applications are submitted during periods set each year by the ANSM, which weighs on your launch schedule. Correspondence answering a professional's specific question about a medicine, with its non-promotional documents, is not advertising (Article L.5122-1). Classifying each use is the job of your responsible pharmacist (pharmacien responsable).
Can a video show a mechanism that is not in the SmPC?
Not in an advertisement: all its elements must comply with the SmPC (Directive 2001/83/EC, Article 87) and, according to the ANSM, a pharmacological property without a clinical consequence validated by the marketing authorisation can be neither its slogan, nor its title, nor its main message. Outside advertising, in the internal training of your teams or in your medical information department's answer to a specific, unsolicited question from a healthcare professional, a mechanism still under discussion can be presented if it is described as such, with the origin of its data: patients, animals or in vitro.
How long does it take to produce a mechanism of action animation?
The first version arrives within a few days of a 30-minute scoping call: up to 60 seconds, in motion design, in the language you choose. The timing of the final version depends mainly on your approval process: scientific review, MLR review, then the ANSM visa if the video is an advertisement shown in France. The justification file is built for that process: every line comes with its reference, its page and the passage that supports it.
Can a biotech show its mechanism of action before marketing authorisation?
Yes, but not in an advertisement: in France, a medicine without a marketing authorisation or another authorisation provided for by the Code cannot be advertised at all (Article L.5122-3 of the French Public Health Code). The video then serves to explain a mechanism or a platform to investors, partners, a scientific committee or future employees. For each step, we state where the data come from, preclinical or clinical, without anticipating a benefit the studies have not yet established.